Developer docs
API playgroundTry for free, no card

Search company profiles

Mubadala Bio

Full company profile

uuid0009tvf

Namestring
Mubadala Bio
Legal namestring
Mubadala Bio
Websiteurl
mubadalabio.ae
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Mubadala Bio is a UAE-headquartered life sciences company launched in 2025 and wholly owned by Mubadala Investment Company. It operates through two integrated verticals: Integrated Biopharma, which manufactures pharmaceuticals across soft gelatin capsules (Bioventure Healthcare, 1.5B capsule capacity), Non-PVC IV fluids and dialysis (WellPharma, 11M bag capacity), sterile Blow-Fill-Seal injectables (Gulf Inject), and biologics via a 10,000-litre DiabTec facility — the only one of its kind in the GCC; and Pharma Logistics, which runs end-to-end distribution through Al Ittihad Drug Store (IDS, serving 100% of UAE hospitals and 3,000+ pharmacies) and Global Medical Supply Chain (GMSC, integrated procurement, warehousing, cold-chain, and supply-chain management for ~190 healthcare facilities).

The business model is institutional B2B: products are sold via negotiated multi-year contracts to hospitals, healthcare systems, pharmacies, and government institutions in the UAE, with exports to 100+ countries enabled by EU GMP, US GMP, and cGMP certifications. Manufacturing revenue is product-based, while logistics revenue combines transaction-fee distribution services and value-add commercialization (regulatory, marketing, sales support) for global pharma brands.

The company serves government health authorities (e.g., UAE Ministry of Defense, University Hospital Sharjah), private hospital networks, retail pharmacies, and international buyers. Its strategic positioning is built on national drug security (UAE) and vertical integration spanning drug substance manufacturing to last-mile delivery, with 3,000+ FTEs across 10 sites in the UAE, Asia, Africa, and Europe.

Short descriptiontext

Mubadala Bio is a UAE-based life sciences company, wholly owned by Mubadala Investment Company, operating Integrated Biopharma (capsules, IV fluids, injectables, biologics) and Pharma Logistics (IDS and GMSC distribution) to serve hospitals, pharmacies, and government institutions across 100+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDubai, United Arab Emirates
HQ citystring
Dubai
HQ countrystring
United Arab Emirates
HQ regionstring
Middle East
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, pharmaceutical distribution, IV fluids production, biologic therapies, pharma logistics
Industry4 codes
PRIMARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYTLAIALAC
Pharmaceuticals & Biopharma
Transportation & Logistics/Third-Party & Fourth-Party Logistics (3PL/4PL) / Contract Logistics/Industry-Specific Contract Logistics (Automotive, Pharma, Retail, Aerospace, etc.)
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Manufacturing & Sales
TypeHardware Sales
Description

Revenue generated from manufacturing and selling pharmaceutical products including soft gelatin capsules (Bioventure Healthcare), IV fluids and dialysis solutions (Wellpharma), sterile injectables (Gulf Inject), and biologic therapies (DiabTec). Products are sold to hospitals, pharmacies, healthcare providers, and exported to international markets across 100+ countries.

mubadalabio.ae
2Pharmaceutical Distribution & Logistics Services
TypeTransaction Fee
Description

Revenue from pharmaceutical logistics and distribution services through IDS and GMSC, providing medical procurement, warehousing, distribution, equipment servicing, and asset management to healthcare providers across the UAE. Services include full cold-chain management and 12–48-hour delivery.

mubadalabio.ae
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1Institutional B2B pricing — negotiated per contract
ModelOtherBilling cadenceMulti-year contract
Notes

Pharmaceutical products and logistics services are sold through B2B contracts with hospitals, healthcare systems, pharmacies, and government institutions. Pricing is negotiated directly and not publicly disclosed.

mubadalabio.ae
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Integrated Biopharma
Description

Vertical focused on advancing development and local production of high-quality, essential drugs by expanding UAE pharmaceutical manufacturing capabilities.

mubadalabio.ae
+1 more record
Core offering1 text field

Mubadala Bio manufactures and distributes pharmaceutical products through two integrated verticals: Integrated Biopharma (pharmaceutical manufacturing including soft gelatin capsules via Bioventure Healthcare, IV fluids and dialysis solutions via Wellpharma, sterile injectables via Gulf Inject, and biologic therapies via DiabTec) and Pharma Logistics (pharmaceutical distribution, warehousing, and supply chain services via IDS and GMSC). The company serves hospitals, pharmacies, healthcare providers, and government institutions across the UAE, Asia, Africa, and Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 2.5 billion capsules produced annually
+6 more records
Product and service6 records
1Soft Gelatin Capsules (Bioventure Healthcare)
CategoryPharmaceutical Manufacturing
2IV Fluids and Dialysis Solutions (Wellpharma)
CategoryPharmaceutical Manufacturing
3Sterile Injectables (Gulf Inject)
CategoryPharmaceutical Manufacturing
4Biologic Therapies (DiabTec)
CategoryBiologics Manufacturing
5Pharmaceutical Distribution Services (IDS)
CategoryPharmaceutical Distribution
6Medical Supply Chain Services (GMSC)
CategoryPharmaceutical Logistics
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-26
Description

Mubadala Bio signed a licensing and supply agreement with Biosidus at BIO International Convention 2026 in San Diego. The partnership is executed through DiabTec, Mubadala Bio's biologics facility in the UAE, supporting the localization of biologic therapies used in endocrinology, nephrology, and oncology. Biosidus provides biotechnology expertise while Mubadala Bio contributes local manufacturing capabilities, reinforcing national drug security.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-22
Description

IDS signed agreements with Bayer to broaden access to a wider portfolio of healthcare products and critical therapies across the UAE, as part of Mubadala Bio's Pharma Logistics expansion.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-22
Description

IDS signed agreements with Globalpharma to broaden access to a wider portfolio of healthcare products and critical therapies across the UAE, as part of Mubadala Bio's Pharma Logistics expansion.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-22
Description

IDS signed an agreement with Valeo Health to enable access to wellness products through online channels, supporting IDS's strategy to reach consumers more easily and flexibly through e-commerce distribution.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-12
Description

Mubadala Bio's IDS signed an exclusive distribution and promotional agreement with L-Nutra at Make it in the Emirates 2026. IDS will exclusively market and distribute L-Nutra's longevity nutrition products, including ProLon and Fast Mimicking Diet products, across the UAE. This partnership reflects Mubadala Investment Company's prior strategic investment in L-Nutra and the establishment of a joint venture in Abu Dhabi for producing longevity-focused nutrition for the MENA region.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

M42 (global health leader powered by AI, technology, and genomics) and Mubadala Bio's GMSC signed an exclusive outsourcing agreement at Make it in the Emirates 2026. GMSC manages a fully integrated supply chain model across M42's healthcare network covering sourcing, procurement, demand planning, warehousing, distribution, and inventory management. The partnership strengthens medical supply chain resilience and operational efficiency across M42's network of world-class healthcare facilities.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Borouge and Mubadala Bio partnered to advance UAE healthcare and life sciences manufacturing, announced May 2025. The partnership aims to strengthen domestic pharmaceutical production capabilities and support the UAE's broader healthcare and life sciences manufacturing ecosystem.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UAE-based pharmaceutical manufacturer with capabilities across generics, biologics, and sterile manufacturing. Comparable to Mubadala Bio's manufacturing footprint in Abu Dhabi and GCC market positioning.

TypeBroad incumbent
Description

Global pharmaceutical and life sciences incumbent. Directly relevant as an existing distribution partner with IDS (Mubadala Bio) and as a broader category incumbent in pharmaceutical products.

TypeBroad incumbent
Description

Global pharmaceutical company with leading biologics and oncology portfolios. Comparable as a partner candidate for DiabTec-style licensing arrangements and as an incumbent competitor in the regional biologics market.

4McKesson
TypeBroad incumbent
Description

Global pharmaceutical distribution and supply chain services leader. Comparable to Mubadala Bio's Pharma Logistics vertical in large-scale drug distribution, warehousing, and institutional supply chain services.

TypeRegional player
Description

Jordan-headquartered multinational pharmaceutical company with strong MENA and US generics, injectables, and biologics businesses. Comparable in regional MENA footprint, regulated manufacturing capabilities, and integrated supply chain model.

TypeRegional player
Description

Saudi Arabia-headquartered pharmaceutical manufacturer and distributor serving the GCC. Comparable regional pharma manufacturer with overlapping generics, injectables, and distribution operations, though Saudi-focused rather than UAE-anchored.

TypeRegional player
Description

Saudi pharmaceutical manufacturer focused on generics and branded products across the MENA region. Comparable regional manufacturer with similar institutional customer base and regulatory certifications, though Saudi-anchored.

TypeBroad incumbent
Description

Global pharmaceutical incumbent with broad portfolio across branded, generics, and biologics. Relevant as an incumbent competitor and partner counterpart (Bayer is a similar partner) for institutional tenders in the UAE.

9Julphar (Gulf Pharmaceutical Industries)
TypeDirect peer
Description

UAE-based pharmaceutical manufacturer producing generics, biosimilars, and consumer health products across multiple dosage forms. Directly comparable to Mubadala Bio's Integrated Biopharma vertical in geography, product mix, and institutional customer base; former employer of Mubadala Bio's Group CEO.

10Julphar Logistics / UAE Pharma Distribution Peers (Emirates Healthcare)
TypeRegional player
Description

UAE-based healthcare distribution and supply chain player serving hospitals and pharmacies. Comparable to Mubadala Bio's Pharma Logistics vertical in hospital and pharmacy distribution across the UAE.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mubadala Bio

Pharmaceutical Manufacturingmubadalabio.ae

Mubadala Bio is a UAE-based life sciences company, wholly owned by Mubadala Investment Company, operating Integrated Biopharma (capsules, IV fluids, injectables, biologics) and Pharma Logistics (IDS and GMSC distribution) to serve hospitals, pharmacies, and government institutions across 100+ countries.

What Mubadala Bio does

Mubadala Bio is a UAE-headquartered life sciences company launched in 2025 and wholly owned by Mubadala Investment Company. It operates through two integrated verticals: Integrated Biopharma, which manufactures pharmaceuticals across soft gelatin capsules (Bioventure Healthcare, 1.5B capsule capacity), Non-PVC IV fluids and dialysis (WellPharma, 11M bag capacity), sterile Blow-Fill-Seal injectables (Gulf Inject), and biologics via a 10,000-litre DiabTec facility — the only one of its kind in the GCC; and Pharma Logistics, which runs end-to-end distribution through Al Ittihad Drug Store (IDS, serving 100% of UAE hospitals and 3,000+ pharmacies) and Global Medical Supply Chain (GMSC, integrated procurement, warehousing, cold-chain, and supply-chain management for ~190 healthcare facilities).

The business model is institutional B2B: products are sold via negotiated multi-year contracts to hospitals, healthcare systems, pharmacies, and government institutions in the UAE, with exports to 100+ countries enabled by EU GMP, US GMP, and cGMP certifications. Manufacturing revenue is product-based, while logistics revenue combines transaction-fee distribution services and value-add commercialization (regulatory, marketing, sales support) for global pharma brands.

The company serves government health authorities (e.g., UAE Ministry of Defense, University Hospital Sharjah), private hospital networks, retail pharmacies, and international buyers. Its strategic positioning is built on national drug security (UAE) and vertical integration spanning drug substance manufacturing to last-mile delivery, with 3,000+ FTEs across 10 sites in the UAE, Asia, Africa, and Europe.

Mubadala Bio firmographics

Firmographics
Name
Mubadala Bio
Legal name
Mubadala Bio
Website
https://mubadalabio.ae
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
51–100 employees
Short description
Mubadala Bio is a UAE-based life sciences company, wholly owned by Mubadala Investment Company, operating Integrated Biopharma (capsules, IV fluids, injectables, biologics) and Pharma Logistics (IDS and GMSC distribution) to serve hospitals, pharmacies, and government institutions across 100+ countries.
Ownership category
akta.pro rank

Mubadala Bio industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYTLAIALAC
Pharmaceuticals & Biopharma
Transportation & Logistics/Third-Party & Fourth-Party Logistics (3PL/4PL) / Contract Logistics/Industry-Specific Contract Logistics (Automotive, Pharma, Retail, Aerospace, etc.)
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

Keywords

  • Pharmaceutical manufacturing
  • Pharmaceutical distribution
  • IV fluids production
  • Biologic therapies
  • Pharma logistics

Where Mubadala Bio is headquartered

Location

Headquarters

HQ city
Dubai
HQ country
United Arab Emirates
HQ region
Middle East

Offices6 records

Markets served

Mubadala Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Manufacturing & Sales: Revenue generated from manufacturing and selling pharmaceutical products including soft gelatin capsules (Bioventure Healthcare), IV fluids and dialysis solutions (Wellpharma), sterile injectables (Gulf Inject), and biologic therapies (DiabTec). Products are sold to hospitals, pharmacies, healthcare providers, and exported to international markets across 100+ countries.
  2. Pharmaceutical Distribution & Logistics Services: Revenue from pharmaceutical logistics and distribution services through IDS and GMSC, providing medical procurement, warehousing, distribution, equipment servicing, and asset management to healthcare providers across the UAE. Services include full cold-chain management and 12–48-hour delivery.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractInstitutional B2B pricing — negotiated per contract

Go-to-market motion2 records

Distribution channels3 records

Marketing channels2 records

Mubadala Bio product offering

Product offering

Core offering

Mubadala Bio manufactures and distributes pharmaceutical products through two integrated verticals: Integrated Biopharma (pharmaceutical manufacturing including soft gelatin capsules via Bioventure Healthcare, IV fluids and dialysis solutions via Wellpharma, sterile injectables via Gulf Inject, and biologic therapies via DiabTec) and Pharma Logistics (pharmaceutical distribution, warehousing, and supply chain services via IDS and GMSC). The company serves hospitals, pharmacies, healthcare providers, and government institutions across the UAE, Asia, Africa, and Europe.

Differentiator

Problem solved

Functional benefit

Brands

  • Integrated Biopharma: Vertical focused on advancing development and local production of high-quality, essential drugs by expanding UAE pharmaceutical manufacturing capabilities.
  • Pharma Logistics

Products and services

  • Soft Gelatin Capsules (Bioventure Healthcare)
  • IV Fluids and Dialysis Solutions (Wellpharma)
  • Sterile Injectables (Gulf Inject)
  • Biologic Therapies (DiabTec)
  • Pharmaceutical Distribution Services (IDS)
  • Medical Supply Chain Services (GMSC)

Quantifiable outcome

  • 2.5 billion capsules produced annually
  • +6 more outcomes

Companies that use Mubadala Bio

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Mubadala Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Mubadala Bio partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, secondary and minor.

  • BiosiduscoreStrategic or Co-development Partner · 26 June 2026Mubadala Bio signed a licensing and supply agreement with Biosidus at BIO International Convention 2026 in San Diego. The partnership is executed through DiabTec, Mubadala Bio's biologics facility in the UAE, supporting the localization of biologic therapies used in endocrinology, nephrology, and oncology. Biosidus provides biotechnology expertise while Mubadala Bio contributes local manufacturing capabilities, reinforcing national drug security.
  • BayersecondaryChannel Partner/ Reseller/ Distributor · 22 June 2026IDS signed agreements with Bayer to broaden access to a wider portfolio of healthcare products and critical therapies across the UAE, as part of Mubadala Bio's Pharma Logistics expansion.
  • GlobalpharmasecondaryChannel Partner/ Reseller/ Distributor · 22 June 2026IDS signed agreements with Globalpharma to broaden access to a wider portfolio of healthcare products and critical therapies across the UAE, as part of Mubadala Bio's Pharma Logistics expansion.
  • Valeo HealthminorChannel Partner/ Reseller/ Distributor · 22 June 2026IDS signed an agreement with Valeo Health to enable access to wellness products through online channels, supporting IDS's strategy to reach consumers more easily and flexibly through e-commerce distribution.
  • L-NutrasecondaryChannel Partner/ Reseller/ Distributor · 12 May 2026Mubadala Bio's IDS signed an exclusive distribution and promotional agreement with L-Nutra at Make it in the Emirates 2026. IDS will exclusively market and distribute L-Nutra's longevity nutrition products, including ProLon and Fast Mimicking Diet products, across the UAE. This partnership reflects Mubadala Investment Company's prior strategic investment in L-Nutra and the establishment of a joint venture in Abu Dhabi for producing longevity-focused nutrition for the MENA region.
  • M42coreStrategic or Co-development Partner · 1 May 2026M42 (global health leader powered by AI, technology, and genomics) and Mubadala Bio's GMSC signed an exclusive outsourcing agreement at Make it in the Emirates 2026. GMSC manages a fully integrated supply chain model across M42's healthcare network covering sourcing, procurement, demand planning, warehousing, distribution, and inventory management. The partnership strengthens medical supply chain resilience and operational efficiency across M42's network of world-class healthcare facilities.
  • BorougesecondaryStrategic or Co-development Partner · 1 May 2026Borouge and Mubadala Bio partnered to advance UAE healthcare and life sciences manufacturing, announced May 2025. The partnership aims to strengthen domestic pharmaceutical production capabilities and support the UAE's broader healthcare and life sciences manufacturing ecosystem.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Mubadala Bio competitors and assessment

Company assessment

Direct peers

  • Neopharma: UAE-based pharmaceutical manufacturer with capabilities across generics, biologics, and sterile manufacturing. Comparable to Mubadala Bio's manufacturing footprint in Abu Dhabi and GCC market positioning.
  • Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer producing generics, biosimilars, and consumer health products across multiple dosage forms. Directly comparable to Mubadala Bio's Integrated Biopharma vertical in geography, product mix, and institutional customer base; former employer of Mubadala Bio's Group CEO.

Broad incumbents

  • Bayer: Global pharmaceutical and life sciences incumbent. Directly relevant as an existing distribution partner with IDS (Mubadala Bio) and as a broader category incumbent in pharmaceutical products.
  • AstraZeneca: Global pharmaceutical company with leading biologics and oncology portfolios. Comparable as a partner candidate for DiabTec-style licensing arrangements and as an incumbent competitor in the regional biologics market.
  • McKesson: Global pharmaceutical distribution and supply chain services leader. Comparable to Mubadala Bio's Pharma Logistics vertical in large-scale drug distribution, warehousing, and institutional supply chain services.
  • Pfizer: Global pharmaceutical incumbent with broad portfolio across branded, generics, and biologics. Relevant as an incumbent competitor and partner counterpart (Bayer is a similar partner) for institutional tenders in the UAE.

Regional players

  • Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company with strong MENA and US generics, injectables, and biologics businesses. Comparable in regional MENA footprint, regulated manufacturing capabilities, and integrated supply chain model.
  • SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi Arabia-headquartered pharmaceutical manufacturer and distributor serving the GCC. Comparable regional pharma manufacturer with overlapping generics, injectables, and distribution operations, though Saudi-focused rather than UAE-anchored.
  • Tabuk Pharmaceuticals: Saudi pharmaceutical manufacturer focused on generics and branded products across the MENA region. Comparable regional manufacturer with similar institutional customer base and regulatory certifications, though Saudi-anchored.
  • Julphar Logistics / UAE Pharma Distribution Peers (Emirates Healthcare): UAE-based healthcare distribution and supply chain player serving hospitals and pharmacies. Comparable to Mubadala Bio's Pharma Logistics vertical in hospital and pharmacy distribution across the UAE.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Mubadala Bio social profiles

Digital presence

Mubadala Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mubadala Bio leadership team

Management profile

Number of profiles

Profiles11 records

Mubadala Bio subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Mubadala Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mubadala Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mubadala Bio

What does Mubadala Bio do?

Mubadala Bio manufactures and distributes pharmaceutical products through two integrated verticals: Integrated Biopharma (pharmaceutical manufacturing including soft gelatin capsules via Bioventure Healthcare, IV fluids and dialysis solutions via Wellpharma, sterile injectables via Gulf Inject, and biologic therapies via DiabTec) and Pharma Logistics (pharmaceutical distribution, warehousing, and supply chain services via IDS and GMSC). The company serves hospitals, pharmacies, healthcare providers, and government institutions across the UAE, Asia, Africa, and Europe.

Is Mubadala Bio a public or private company?

Mubadala Bio is a private company. It is classified as state government owned and is currently operating.

When was Mubadala Bio founded?

Mubadala Bio was founded in 2025. It employs 51 to 100 people.

Where is Mubadala Bio based?

Mubadala Bio is headquartered in Dubai, United Arab Emirates, in the Middle East region.

How does Mubadala Bio make money?

Two revenue lines are on record. Pharmaceutical Manufacturing & Sales are the primary driver. The others are pharmaceutical Distribution & Logistics Services.

Who are Mubadala Bio's main competitors?

Direct peers on record are Neopharma and Julphar (Gulf Pharmaceutical Industries). Broad incumbents are Bayer, AstraZeneca, McKesson and Pfizer. Regional players are Hikma Pharmaceuticals, SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), Tabuk Pharmaceuticals and Julphar Logistics / UAE Pharma Distribution Peers (Emirates Healthcare).

Does Mubadala Bio have an API?

No public API is recorded for Mubadala Bio.

What industry is Mubadala Bio in?

Mubadala Bio's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors, with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 325412 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialPODTECHTM Completes Prefabricated Modular Bio-Pharma Manufacturing Facility For Mubadala Bio's Bioventure HealthcarePODTECHTM completed a prefabricated modular bio-pharma facility for Bioventure Healthcare, a Mubadala Bio subsidiary, to manufacture hormone medicines. The 14-unit facility covers 250 sqm and includes ISO 8 cleanrooms, labs, and HVAC systems. The project was delivered in months, with PODTECHTM claiming it can cut schedules by up to 50%.Business & FinancialPODTECHTM Completes Prefabricated Modular Bio-Pharma Manufacturing Facility For Mubadala Bio's Bioventure HealthcarePODTECHTM completed a prefabricated modular bio-pharma facility for Bioventure Healthcare, a Mubadala Bio subsidiary, to manufacture hormone medicines. The 250 sqm facility includes 14 PODULETM units with ISO 8 cleanrooms and labs, delivered in months. The project aims to cut schedules by up to 50% versus traditional construction.Business & FinancialLilly And Mubadala Bio Announce Landmark Agreement To Advance Pharmaceutical Contract Manufacturing In Abu DhabiEli Lilly and Mubadala Bio announced a partnership to advance pharmaceutical contract manufacturing in Abu Dhabi at the Abu Dhabi Future Health Summit 2026. The collaboration will use a 125,000 sqm KEZAD site for packaging and warehousing, aiming to strengthen the UAE's life sciences ecosystem. Localized packaging and logistics activities will be introduced in phases.EIN PresswireEli Lilly, Mubadala Bio sign deal for advance pharma contract manufacturing Abu DhabiEli Lilly and Mubadala Bio announced a collaboration to advance packaging and logistics for Lilly's GLP-1 medicines in Abu Dhabi. The partnership will use a 125,000 sq m KEZAD site for contract manufacturing and logistics. The UAE recently approved Foundayo for weight management, and the UAE was an early launch market for Mounjaro.ZawyaLilly, Mubadala Bio announce landmark deal to advance pharmaceutical manufacturing in Abu DhabiEli Lilly and Mubadala Bio announced a partnership to advance pharmaceutical manufacturing in Abu Dhabi, supported by a 125,000 sqm site in KEZAD. The collaboration aims to build advanced pharmaceutical capabilities and strengthen the UAE's life sciences ecosystem. The UAE recently approved Foundayo for chronic weight management, making it the second country to register the medicine.EIN PresswireWeight-loss drugs Mounjaro and Foundayo to be packaged in UAE | The NationalEli Lilly signed a deal with Mubadala Bio to package weight-loss drugs Mounjaro and Foundayo in the UAE for regional distribution. The contract-manufactured medicines will support reliable access and strengthen the UAE's life-sciences supply chain. The company aims to reduce obesity rates from 32% to 18% by 2031.IndexBoxMubadala Bio Introduces Locally Produced Hemodialysis Concentrate Solutions in Abu DhabiMubadala Bio has introduced the first UAE-made hemodialysis concentrate solutions via its subsidiary Wellpharma, which operates a manufacturing facility in Abu Dhabi, launching eight hospital-grade hemodialysis products for patients with kidney failure. The company stated that local production ensures a more reliable supply of vital therapies for patients dependent on dialysis while strengthening the UAE's domestic pharmaceutical manufacturing capabilities. Executives described the launch as a significant milestone in advancing the country's life sciences sector and supporting its goal of becoming a leading healthcare hub.ZawyaMubadala Bio launches first locally manufactured hemodialysis solutions in the UAEMubadala Bio launched eight hospital-grade hemodialysis solutions through its Abu Dhabi-based Wellpharma facility, marking the first local UAE production of hemodialysis concentrate solutions. The products are designed to support dialysis procedures for patients with kidney failure, ensuring consistent supply of critical therapies.El CronistaCómo un laboratorio argentino logró entrar al exclusivo mercado de Emiratos ÁrabesArgentine pharmaceutical company Biosidus signed an agreement with Mubadala Bio, a subsidiary of Abu Dhabi's sovereign wealth fund, to register, distribute, and commercialize four biosimilars in the United Arab Emirates, Iraq, and Bahrain. The deal was signed at the BIO international convention in San Diego, with the first exports expected between late 2024 and early 2027; the UAE market is particularly strategic for Biosidus as it currently exports around 70% of its total production. The agreement originated from a previous partnership Biosidus established two years ago in Algeria, which sparked interest from regional players, and the company has identified Saudi Arabia as its next expansion target.ZawyaMubadala Bio partners with Biosidus to advance access to biologic therapiesMubadala Bio signed a licensing and supply agreement with Biosidus at BIO 2026, to be executed through DiabTec, its UAE biologics facility. The partnership aims to localize biologics for endocrinology, nephrology, and oncology, advancing Mubadala Bio's drug security mission.